No annual revenue total was found in Skye Bioscience, Inc.'s SEC filings.
Skye Bioscience, Inc. (SKYE) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$43.1 million. As of Jun 30, 2026 it held $10.1 million in cash and investments and $35,696 in total debt.
Revenue
—
Net income (TTM)
$-50.49M
-19.2% vs year-ago TTM
Operating cash flow (TTM)
$-38.81M
-16.3% vs year-ago TTM
Free cash flow (TTM)
$-38.81M
-11.1% vs year-ago TTM
EPS (TTM)
$-1.27
-19.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
33.38M
+7.8% vs prior year
Net cash
$10.03M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SKYE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1516551
- Former names
- Emerald Bioscience, Inc. (until Jan 7, 2021); Nemus Bioscience, Inc. (until Mar 14, 2019); LOAD GUARD LOGISTICS, INC. (until Oct 30, 2014); LOAD GUARD TRANSPORTATION, INC. (until Nov 7, 2012)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$58.2M | -$30.2M | -$34.7M | -$18.3M | -$7.8M |
| Net income | -$55.9M | -$26.6M | -$37.6M | -$19.5M | -$8.5M |
| Diluted EPS | -$1.41 | -$0.73 | -$5.37 | -$8.77 | -$0.02 |
| Operating cash flow | -$43.1M | -$25.2M | -$14.0M | -$12.7M | -$6.5M |
| Free cash flow | -$43.1M | -$26.8M | -$14.0M | -$12.8M | -$6.6M |
| Total assets | $28.3M | $72.8M | $11.9M | $9.1M | $9.9M |
| Total liabilities | $8.3M | $4.6M | $14.1M | $12.1M | $4.0M |
| Stockholders' equity | $20.0M | $68.2M | -$2.1M | -$3.0M | $5.9M |
| Cash and investments | $25.7M | $68.4M | — | — | — |
| Total debt | $273,646 | $455,590 | $243,268 | $78,700 | $161,072 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Agreement ended, Officer or director change, Other events
|
Sep 11, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Aug 24, 2026 | Aug 21, 2026 |
| 8-K/A |
Amended current report
Change to shareholder rights
|
Aug 20, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Listing notice
|
Aug 19, 2026 | Aug 18, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change to shareholder rights, Change in control, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure
|
Aug 14, 2026 | Aug 12, 2026 |
All 631 Skye Bioscience, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.